CRBP · Corbus Pharmaceuticals Holdings, Inc.
$10.09
+0.01 (+0.10%)
At close · Aug 14
Market Cap
$195.15M
Shares
19.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.09
Open$10.04
Day$9.88–10.29
52W close$7.38–19.36
Avg vol 30d309K
Short int2.3M · 11.9% float · 9.4d
Short vol28%
Last earningsMar 15, 2021
DataFeb 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Feb 14, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+13%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+36%
trailing
YTD return
+24%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $9 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +25 funds added
Insider flow
Accumulating
Net +$126.3K over 90 days · 0% sells
Short interest
Rising
11.89% of float · ▲ +9.7% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
106 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+98%
Y/Y
EPS growth
−60%
Y/Y
Free cash flow
$-64.5M
Balance sheet
$12.6M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $9 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +25 funds added
Insider flow
Accumulating
Net +$126.3K over 90 days · 0% sells
Short interest
Rising
11.89% of float · ▲ +9.7% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
106 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $10 · 23%
Range high $19
vs 200-day avg +7%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRBP
this stock
Corbus Pharmaceuticals Holdings, Inc.
|
$195.15M | +24.0% | +97.6% | — | 11.9% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Feb 14, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRBP | -0.8% | +12.0% | +36.0% | +12.5% | +24.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.2% | +7.5% | +22.2% | +8.6% | +10.1% |
Key facts
CIK
1595097
CUSIP
21833P301
13F (30d)
102 filings
100 filers
Visit website
Investor relations